183208-34-6

Basic information

• Product Name: 5-BROMO-1H-PYRROLO[2 , 3-B]PYRIDIN-2(3H)-ONE
• Synonyms: 5-BROMO-1H-PYRROLO[2 , 3-B]PYRIDIN-2(3H)-ONE;5-Bromo-7-Aza-Indolin-2(3h)-One;2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-1,3-dihydro-;5-Bromo-1H-pyrrolo[2,3-b]pyridin-2-one;5-Bromo-1H-pyrrolo[2,3-b]...;5-Bromo-7-aza-2-oxindole;5-broMo-1H-pyrrolo[2;5-Bromo-2,3-dihydro-7-azaindole-2-one
• CAS NO: 183208-34-6
• Molecular Formula: C₇H₅BrN₂O
• Molecular Weight: 213.0314
• EINECS: 200-589-5
• Product Categories: CHIRAL CHEMICALS
• Mol File: 183208-34-6.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 387.799 °C at 760 mmHg
• Flash Point: 188.335 °C
• Appearance: /
• Density: 1.768 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 0.472mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 1.98±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-1H-PYRROLO[2 , 3-B]PYRIDIN-2(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1H-PYRROLO[2 , 3-B]PYRIDIN-2(3H)-ONE(183208-34-6)
• EPA Substance Registry System: 5-BROMO-1H-PYRROLO[2 , 3-B]PYRIDIN-2(3H)-ONE(183208-34-6)

Safety Data

• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 183208-34-6(Hazardous Substances Data)

Usage

Chemical Properties

Pink powder

Upstream product

• 183208-32-4 3,3,5-Tribromo-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 271-63-6 7-Azaindole 
• 92635-29-5 3,3,5-tribromo-2-oxindole 
• 113423-51-1 3,3-Dibromo-1,3-dihydro-2H-pyrrolo[2,3-b]-pyridin-2-one 
• 13939-06-5 molybdenum hexacarbonyl 
• 206997-15-1 2-amino-5-bromo-3-pyridinecarbaldehyde 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 189563-97-1 5-Vinyl-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 223646-21-7 ethyl 2-oxo-2,3-dihydro-1H-pyrollo[2,3-b]pyridine-5-carboxylate 
• 371758-71-3 5-(2-thienyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 223646-08-0 5-phenyl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 1207623-97-9 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one 
• 916895-89-1 7-azaserotonin 
• 183208-36-8 5-methoxy-1H-pyrrolo[2,3-b]pyridine 
• 183208-38-0 3-formyl-5-methoxy-1H-pyrrolo<2,3-b>pyridine 
• 183208-22-2 5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine 
• 189563-98-2 2-Oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde 
• 189563-99-3 5-(Hydroxy-phenyl-methyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 611204-90-1 5-(3-fluoro-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 1111637-70-7 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ylboronic acid 

Relevant articles and documents

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors

Five novel 1H-pyrrolo[2,3-b]pyridine or 1H-pyrazolo[3,4-b]pyridine derivatives, with a methylene, sulfur, sulfoxide or cyclopropyl group as a linker, were designed, synthesized and biologically evaluated against c-Met and ALK. The development of these methods of compound synthesis may provide an important reference for the construction of novel 7-azaindole and 7-azaindazole derivatives with a single atom linker. The enzyme assay and cell assay in vitro showed that compound 9 displayed strong c-Met kinase inhibition with IC50 of 22.8 nM, moderate ALK kinase inhibition, and strong cell inhibition with MKN-45 IC50 of 329 nM and EBC-1 IC50 of 479 nM. In order to find the better candidate compounds, compounds 8, 9 and 10 have been selected as tool compounds for further optimization.